WESTPORT, Conn., May 14, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that Lewis H. Bender, President and CEO, will present a poster on the preclinical and early Phase 1/2 data of its lead product candidate, INT230-6, at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy Symposium being held May 14-15, 2019 in New York, NY at 7 World Trade Tower 40th Floor.
The poster will examine the preclinical activity of INT230-6 as a monotherapy and in combination with anti-PD-1 antibodies. In addition, the poster will evaluate data from the ongoing Phase 1/2 clinical trial of INT230-6 as a monotherapy in 14 solid tumor cancers, showing an increase in systemic CD4 and CD8 cells with evidence of tumor necrosis and abscopal effects.
About Intensity Therapeutics
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor to diffuse therapeutic agents into cancer cells. Intensity’s product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. INT230-6, Intensity’s lead product candidate, is being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumors. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.
Forward Looking Statements
This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
Contacts
Investors:
Kerry Conlin
Stern Investor Relations
212-698-8685
kerry.conlin@sternir.com
Media:
Claire LaCagnina
6 Degrees PR
(315) 765-1462
clacagnina@6degreespr.com